Curvebeam Ai (CVB.AX) traded down -4.76 % during a 24 hours period ending at 01:57 PM Central Europe on Tuesday 27th. One Curvebeam Ai stock can currently be bought for about AUD 0.02 on popular exchanges. Current supply of Curvebeam Ai stocks is 806.5 mn. Curvebeam Ai has a current market capitalization of AUD 16.1 mn and approximately AUD 10 k worth of Curvebeam Ai was traded on exchanges in the last 24 hours. Since last month end, Curvebeam Ai has traded -13.04 % down. Simple moving average of last 200 days is at AUD 0.04. The highest price of past 52 weeks was recorded at AUD 0.13 on 10/30/2025. 52 weeks low was at AUD 0.02 on 07/17/2026.

Summary of the latest news for Curvebeam Ai

CurveBeam AI Limited has recently filed an initial director’s interest notice with the Australian Securities Exchange. The notice discloses that Daniel A. Pryor, who was appointed on 25 October 2026, holds a significant number of ordinary shares and share rights in the company. No other notable interests or contracts have been reported in the filing. The disclosure, made in compliance with listing rule 3.19A.1, provides the market with transparency regarding the director’s holdings but does not indicate any immediate changes to the company’s financial position or strategic direction.

Here is how related stocks have performed in the past 24 hours:

  • Soar Ai (SOAR) traded down -10.84 % and now trades at USD 0.22. Soar Ai has a market capitalisation of USD 13.3 mn.

  • Biocardia (BCDA) traded down -2.17 % and now trades at USD 0.9. Biocardia has a market capitalisation of USD 13.3 mn.

  • Pasithea Therapeutics (KTTA) traded down -1.23 % and now trades at USD 0.4. Current market capitalisation for Pasithea Therapeutics is USD 13.5 mn.

  • Bionano Genomics (BNGO) traded up 2.65 % and now trades at USD 1.16. Bionano Genomics has a market capitalisation of USD 13.5 mn.

  • Tscan Therapeutics (TCRX) traded down -6.4 % and now trades at USD 0.19. Current market capitalisation for Tscan Therapeutics is USD 13.6 mn. TScan Therapeutics, Inc. has filed a definitive proxy statement for a special meeting of stockholders to be held online on November 20, 2026. The meeting will focus on two proposals: a reverse stock‑split amendment to the company’s certificate of incorporation and a potential adjournment of the meeting should sufficient proxy support not be secured. The board recommends a vote in favour of both proposals, citing the need to raise the share price of the company’s Nasdaq‑listed common stock to meet listing requirements and to enhance liquidity and investor interest. Stockholders are invited to register and vote electronically or by proxy, with instructions and deadlines detailed in the proxy materials. The company will announce preliminary results at the meeting and file a Form 8‑K with final outcomes within four business days.

About Curvebeam Ai

CurveBeam AI Limited is a health care technology company based in Melbourne, Australia. The company specializes in designing, manufacturing, and selling diagnostic cone beam CT scanners. Their platform offers point of care imaging solutions with artificial intelligence and deep learning AI, particularly focused on orthopedics and bone health (fragility fracture prevention). This technology aims to improve patient outcomes by providing more accurate and efficient imaging techniques. CurveBeam AI operates globally, and you can find more information about their products and services on their website, www.curvebeamai.com , or through trading on the ASX All Markets.